button bars forest bayes pooled summary circles
 
deaths (OS)

mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative

versus Standard of Care (SoC)
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 0.80 [0.61; 1.05], 1 RCT, I2=0%
inconclusive result

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons